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OBJECTIVES The Southwest German Interventional Study in Acute Myocardial Infarction (SIAM III)
investigated potentially beneficial effects of immediate stenting after thrombolysis as opposed
to a more conservative treatment regimen.
BACKGROUND Treatment of acute myocardial infarction (AMI) by thrombolysis is compromised by
Thrombolysis In Myocardial Infarction (TIMI) 3 flow rates of only 60% and high
re-occlusion rates of the infarct-related artery (IRA). Older studies showed no benefit of
coronary angioplasty after thrombolysis compared with thrombolytic therapy alone. This
observation has been challenged by the superiority of primary stenting over balloon
angioplasty in AMI.
METHODS The SIAM III study was a multicenter, randomized, prospective, controlled trial in patients
receiving thrombolysis in AMI (12 h). Patients of group I were transferred within 6 h after
thrombolysis for coronary angiography, including stenting of the IRA. Group II received
elective coronary angiography two weeks after thrombolysis with stenting of the IRA.
RESULTS A total of 197 patients were randomized, 163 patients fulfilled the secondary (angiographic)
inclusion criteria (82 in group I, 81 in group II). Immediate stenting was associated with a
significant reduction of the combined end point after six months (ischemic events, death,
reinfarction, target lesion revascularization 25.6% vs. 50.6%, p  0.001).
CONCLUSIONS Immediate stenting after thrombolysis leads to a significant reduction of cardiac events
compared with a more conservative approach including delayed stenting after two
weeks. (J Am Coll Cardiol 2003;42:634–41) © 2003 by the American College of
Cardiology Foundation
Prompt and permanent restoration of epicardial blood flow
and tissue level perfusion is the prominent goal of treatment
strategies after myocardial infarction (MI) (1–3). Throm-
bolytic therapy alone accomplishes Thrombolysis In Myo-
cardial Infarction (TIMI) 3 flow in only 60% of the patients
(1) and is prone to recurrent ischemia before hospital
discharge in 29% (4). Notably, re-occlusion of the infarct-
related artery (IRA) is associated with increased mortality
(5). Prediction of infarct vessel patency by electrocardio-
gram and other non-invasive markers of reperfusion is
limited (6).
See page 642
Primary angioplasty offers several advantages compared
with thrombolysis: higher recanalization rates, direct and
immediate verification of procedural success, and additional
information concerning the left ventricular (LV) function.
Consequently, angioplasty appears to be superior to throm-
bolysis with respect to survival and reinfarction rates (7).
The main limitation of primary angioplasty is its limited
availability (8). Patients treated with angioplasty derive
benefit compared with thrombolysis only when transfer can
be expedited without delay (9,10). Furthermore, patients
with acute MI (AMI) treated at hospitals with low angio-
plasty volumes show similar outcomes with primary angio-
plasty or thrombolysis (11).
The rationale for a combination of thrombolysis and
angioplasty is the rapid onset of reperfusion therapy accom-
panied by reassurance of vessel patency, although data
supporting this concept are lacking. However, older studies
showed no benefit of early angioplasty after thrombolysis
compared with thrombolytic therapy alone (12). More
recent investigations demonstrated superiority of primary
stenting in AMI over angioplasty (13,14). It may be
assumed that coronary stents may overcome the limitations
of balloon angioplasty after thrombolysis by preventing early
re-occlusions. However, there are no data available on the
effects of immediate stenting compared with delayed inter-
vention in patients with AMI after thrombolysis. To exam-
ine the effects of percutaneous coronary intervention we
designed the Southwest German Interventional Study in
Acute Myocardial Infarction (SIAM III) comparing the
strategy of immediate stenting with a more conservative
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approach including elective stenting after stabilization of the
patients condition (i.e., two weeks after the acute event and
thrombolysis).
METHODS
Selection of patients. The SIAM III study was a prospec-
tive, controlled, randomized multicenter trial among pa-
tients with AMI enrolled from July 1998 to April 2001.
Patients were recruited from community hospitals without
cathlab facilities located within a distance to the interven-
tional center up to 35 km. Each patient gave informed
consent. The study protocol was approved by the ethics
committee of the state medical board. Table 1 shows the
inclusion and exclusion criteria.
Drug regimens and treatment strategies. Reteplase
(Rapilysin, Hoffmann-La Roche AG, Grenzach-Wyhlen,
Germany) was administered in two boluses of 10 MU 30
min apart. Patients received 250 mg of aspirin intravenously
(Aspisol, Bayer Vital, Germany) and a bolus of 5,000 IU
heparin. Heparin was continued by an infusion of 1,000
IU/h. The initial rate of heparin infusion was reduced to
800 U/h for patients weighing 80 kg and was adjusted to
maintain an activated partial thromboplastin time of 50 to
70 s in all patients.
During thrombolysis in the primary hospital, the patients
were randomized either to immediate stenting (group I) or
elective stenting (group II) using a computer algorithm.
Patients of group I were transferred to the interventional
center within 6 h after thrombolysis for coronary angiogra-
phy, including stenting of the IRA followed by a second
coronary angiography after two weeks. Group II had elec-
tive coronary angiography after two weeks with stenting of
the IRA, or earlier in case of ongoing ischemia. The patients
received optimal medical treatment, including use of glyco-
protein (GP) IIb/IIIa inhibitors according to the judgment
of the treating physician.
Catheterization procedure and angiographic analysis.
Cardiac catheterization was carried out through the right or
left femoral artery. Additional heparin was given in the
cathlab depending on the activating clotting time, with a
target of 250 s. Aspirin and clopidogrel were continued for
four weeks. The MultiLink stent (Duet, Tetra, Guidant
GmbH, Isernhagen, Germany) was used.
Primary interventional success was defined as stent im-
planted, residual stenosis 15%, and TIMI grade 3 flow
after stent implantation. The index lesion was evaluated
with the CAAS-II System (Pie Medical, Rotterdam, The
Netherlands). Biplane LV angiography was used to evaluate
measures of LV function. Ejection fraction was calculated
by end-diastolic and end-systolic LV area and averaged
between frontal and lateral view. The observers were
blinded to the treatment.
Follow-up and study end points. Patients were inter-
viewed about their medical history and cardiovascular risk
factors, and previous patient records were reviewed. During
the acute phase of MI, serum creatine kinase levels and
creatine kinase-MB fractions were measured every 4 h. All
participants had invasive monitoring of hemodynamic pa-
Table 2. Baseline Data of Secondary Excluded and
Included Patients
Excluded Included
p
Value
n 34 163
Male gender 76.5% 78.5% 0.474
Age 68  13 yrs 63  11 yrs 0.017
Diabetes mellitus 20.6% 31.9% 0.134
Time from symptom onset
to thrombolysis
3.2  1.9 h 3.4  2.4 h 0.710
CK 833  732 U/l 951  781 U/l 0.566
CK-MB 135  126 U/l 121  97 U/l 0.683
Three-vessel disease 58.8% 27.0% 0.001
Left ventricular ejection
fraction
56.8  12.9% 54.7  12.4% 0.422
Cardiogenic shock at
randomization
0 2.5% 0.466
CK  creatine kinase.
Abbreviations and Acronyms
AMI  acute myocardial infarction
GP  glycoprotein
IRA  infarct-related artery
LV  left ventricular
MI  myocardial infarction
SIAM III  Southwest German Interventional Study in
Acute Myocardial Infarction
TIMI  Thrombolysis In Myocardial Infarction
Table 1. Inclusion and Exclusion Criteria of the Study
Primary inclusion criteria:
Age 18 yrs
Patients presenting with symptoms of MI present for 12 h and
having, on the basis of 12-lead electrocardiography, ST-segment
elevation of at least 1 mm in two or more limb leads, ST-segment
elevation of at least 2 mm in the precordial leads, or new bundle-
branch block
Patients eligible for thrombolysis, which means no history of stroke or
central nervous system damage, recent major surgery, systolic blood
pressure 200 mm Hg, or diastolic blood pressure 110 mm Hg
at any time after arrival, no recent noncompressible vascular
puncture, or concomitant use of an oral anticoagulant with an
international normalized ratio 2
No secondary or iatrogenic infarction
No chronic renal insufficiency requiring dialysis
Informed consent for participation
Secondary angiographic inclusion criteria:
Indication for angioplasty independent of the study
Infarct-related lesion in a native coronary artery 2.5 mm
Diameter stenosis of at least 70% or TIMI flow grade 3
Secondary angiographic exclusion criteria:
Coronary anatomy unsuitable for stent placement
Anticipated indication for surgical coronary revascularization within
6 months
Previous MI in the area of the infarct-related vessel
Infarct-related lesion not clearly defined
MI  myocardial infarction; TIMI  Thrombolysis In Myocardial Infarction.
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rameters. The patients were followed up with telephone
interviews at two, four, and six months. Patient records were
reviewed in the case of repeated hospitalization. Repeated
coronary angiography was scheduled after six months.
The primary end point was a combined end point of
death, reinfarction, ischemic events, and target lesion revas-
cularization at six months. “Reinfarction” was defined as
two or more of the following criteria: chest pain lasting for
more than 30 min; a new significant ST-elevation; and a rise
in the serum creatine kinase level to 3 the upper normal
limit. “Target lesion revascularization” was defined as any
reintervention or coronary artery bypass graft surgery involv-
ing the infarct-related vessel. Ischemic events included
unplanned hospitalization and/or unplanned angiography
due to postinfarction angina, recurrent angina pectoris
lasting for more than 15 min despite the administration of
nitrates or being accompanied by electrocardiographic
changes, pulmonary edema, or hypotension. Left ventricular
Figure 1. Flow chart of randomization. r-PA  reteplase.
Table 3. Baseline Data: Comparison of Randomization Groups
Immediate
Stenting
Delayed
Stenting
p
Value
n 82 81
Male gender 76.8% 80.2% 0.367
Age 62.4  11.2 yrs 63.4  9.9 yrs 0.562
Time from symptom onset to thrombolysis 3.2  2.2 h 3.6  2.6 h 0.273
CK 945  874 IU/l 969  684 IU/l 0.860
CK-MB 125  101 IU/l 116  95 IU/l 0.629
Cardiogenic shock at randomization 3.7% 1.2% 0.315
Anterior wall infarction 43.9% 40.7% 0.401
Diabetes mellitus 29.3% 34.6% 0.289
Smoker 42.7% 38.3% 0.340
Hypertension 62.2% 63.0% 0.524
Hyperlipidemia 51.2% 60.5% 0.150
In-hospital medical treatment
-blocker 77.3% 76.2% 0.525
Nitrates 57.6% 77.8% 0.012
ACE inhibitors 93.9% 93.7% 0.615
AT antagonists 1.5% 1.6% 0.740
Statins 62.1% 57.1% 0.346
ACE  angiotensin-converting enzyme; AT antagonists  angiotensin receptor antagonists; CK  creatine kinase.
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ejection fraction was evaluated at baseline in group I and
compared between the groups after two weeks and six
months.
Major bleeding included need for transfusion, bleeding
requiring surgical intervention with a timely connection
with the coronary intervention, bleeding documented by
computed tomography and/or ultrasound, intracerebral as
well as ocular, retroperitoneal, abdominal, intestinal, or
urogenital, or a decrease in hemoglobin 4 g% within 72 h
with a timely connection with the coronary intervention.
Statistical analysis. Final enrollment of 163 patients ran-
domly assigned to either immediate stenting or delayed
stenting, with a two-sided type I error rate of 0.05, yielded
90% power to detect a decrease in the incidence of the
primary end point from 50% to 25% by immediate stenting.
The assumption of these event rates was based on SIAM I
and II results (unpublished data).
Comparisons between the two treatment groups were
performed on an intention-to-treat basis, unless otherwise
specified. Continuous data are expressed as mean  SD.
Categorical variables were compared using the chi-square
test, and continuous variables were compared using the
Student t test. The effect of randomized treatment on
event-free survival was determined by a Kaplan-Meier
survival analysis. Statistical analysis was performed with the
software package SPSS 10.0 for Windows (SPSS Inc.,
Chicago, Illinois).
RESULTS
A total of 197 patients were randomized; 34 patients met
the secondary exclusion criteria due to an indication for
coronary bypass grafting (n 17), a non-significant infarct-
related lesion (i.e., diameter stenosis of 70% including
TIMI 3 flow; n  13), or an undefined IRA (n  4). Table
2 shows the baseline data of all patients. A total of 163
patients were finally included (Fig. 1). There were no
relevant differences in baseline data between the two study
Table 4. Angiographic Data: Comparison of Randomization Groups
Immediate Stenting Delayed Stenting p Value
n 82 81
Time from symptom onset to first angiography 6.7  2.9 h 11.7  6.8 days 0.001
Time from thrombolysis to angiography 3.5  2.3 h 11.7  6.8 days 0.001
Unplanned prior angiography 0 23.5% 0.001
Two-week angiography during initial hospital stay 61.0% 79.0% 0.009
Three-vessel disease 28.0% 25.9% 0.449
Infarct-related vessel
LAD 41.5% 37.0%
CX 11.0% 8.6% 0.672
RCA 47.6% 54.3%
Lesion type
A 1.2% 1.3%
B 40.2% 55.0% 0.166
C 58.5% 43.8%
Angiographic evidence of thrombus formation 62.2% 39.5% 0.003
Abciximab 9.8% 16.0% 0.167
TIMI flow before intervention
0/1 21.0% (5.8% with collaterals) 24.3% (11.1% with collaterals)
2 18.5% 16.2% 0.892
3 60.5% 59.5%
Stent diameter 3.4  0.4 mm 3.4  0.5 mm 0.762
Stent length 20.3  7.4 mm 20.5  9.7 mm 0.878
# Stents 1.1  0.5 1.0  0.6 0.350
Reference diameter before intervention 3.1  0.6 mm 3.1  0.7 mm 0.962
Minimal lumen diameter before intervention 0.4  0.3 mm 0.4  0.4 mm 0.924
Diameter stenosis before intervention 85.8  10.8% 84.9  14.4% 0.664
Reference diameter post-intervention 3.3  0.4 mm 3.3  0.5 mm 0.642
Minimal lumen diameter post-intervention 3.0  0.6 mm 2.9  0.8 mm 0.637
Diameter stenosis post-intervention 9.6  15.2% 12.3  20.6% 0.372
Acute vessel occlusion/no reflow in cath lab 4.9% 6.2% 0.492
TIMI 3 flow post intervention 97.5% 91.9% 0.204
TIMI 3 flow after 2 weeks 98.6% 58.9% 0.001
Reference diameter after 6 months 3.0  0.5 mm 3.1  0.8 mm 0.457
Minimal lumen diameter after 6 months 2.1  0.9 mm 1.8  1.0 mm 0.081
Diameter stenosis after 6 months 31.5  25.3% 43.4  27.7% 0.015
Late lumen loss 0.93  0.86 mm 1.19  0.92 mm 0.113
Binary restenosis rate 25.0% 36.2% 0.126
TIMI 3 flow after 6 months 95.5% 91.2% 0.619
CX  circumflex artery; LAD  left anterior descending coronary artery; RCA  right coronary artery; TIMI  Thrombolysis In Myocardial Infarction.
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groups (Table 3). Angiographic data were comparable
between the two groups (Table 4); TIMI 3 flow rates at
two-week angiography were 98% in group I vs. 59% in
group II (p  0.001).
Major bleeding complications occurred in 9.8% of pa-
tients with immediate stenting versus 7.4% in delayed
stenting (p  0.374). At randomization, three patients in
the immediate-stenting group and one patient in the elec-
tive group were in cardiogenic shock. The three patients in
group I were transferred to the interventional center for
angiography after 1.2, 1.4, and 5.2 h, respectively. The
patient in group II presenting with cardiogenic shock was
transferred for premature angiography 3.4 h after the initial
treatment. All patients with cardiogenic shock received an
intra-aortic balloon pump. During follow-up, two patients
with immediate intervention and six patients in the elective
group developed a new episode of cardiogenic shock.
Cerebral bleeding after thrombolysis occurred in one patient
of group I and two patients of group II. Five patients of
group II died in the first 48 h after thrombolysis, whereas all
patients of group I survived the acute phase.
A total of 19 patients (23.5%) in group II underwent
unplanned premature angiography 3.1  4.2 days after
thrombolysis due to persistent electrocardiographic signs of
ischemia (n  9), postinfarction angina pectoris (n  9),
and hemodynamic instability (n  1). During a mean
follow-up time of 287  225 days, immediate stenting was
associated with a significant reduction of the combined end
point (ischemic events, death, reinfarction, target lesion
revascularization; 25.6% vs. 50.6%, p  0.001; Fig. 2). This
beneficial effect was driven mainly by the reduction of
ischemic events (4.9% vs. 28.4%, p  0.01; Table 5). On an
intention-to-treat basis, immediate stenting lead to a sig-
nificant reduction of death, reinfarction, and target lesion
revascularization (27.7% vs. 39.8%, p  0.049; Table 6).
Patients with and without reperfusion after thrombolysis
undergoing immediate stenting showed similar outcomes in
contrast with those patients with delayed stenting (Table 7).
Patients with immediate stenting showed a LV ejection
fraction of 52.2  12.6% immediately after thrombolysis.
Left ventricular function after two weeks was significantly
better in patients undergoing immediate stenting than in
the elective group (56.7  11.5% vs. 52.5  13.1%, p 
0.037). After six months, patients in the group of immediate
stenting showed a further improvement in LV function
from 56.7  11.5% to 61.5  12.0% (p  0.015), whereas
the difference in the delayed stenting group failed the
statistical significance (from 52.5 13.1% to 56.4 11.4%,
p  0.082) (Table 5).
DISCUSSION
Thrombolysis is regarded as the standard treatment for
AMI. Percutaneous coronary intervention with stenting
Figure 2. Event-free survival (freedom from death, reinfarction, target lesion reintervention, or ischemic events), comparison of randomization groups.
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(13) in combination with GP IIb/IIIa antagonists (14)
appears to be superior to thrombolysis (15). However, this
requires immediate transfer to an experienced interventional
center, which often poses logistical problems and a loss of
time. The additional time delay in the Air Primary Angio-
plasty in Myocardial Infarction (AIR-PAMI) trial for trans-
fer to primary angioplasty was about 52 min (16). Throm-
bolysis, in contrast, is available without delay. Coronary
intervention immediately after thrombolysis could be an
attractive option to cover this gap and improve the limited
patency rates. However, randomized trials in the late 1980s
and early 1990s have shown no advantage of immediate and
early intervention after thrombolysis (12). There was no
improvement in mortality, LV function, or rates of re-
occlusion. In contrast, early coronary angioplasty was asso-
ciated with higher rates of bleeding and transfusions and
emergency coronary artery bypass grafting. In some studies,
in fact, the more aggressive approach with early coronary
Table 5. End Points: Comparison of Randomization Groups
Immediate Stenting Delayed Stenting p Value
n 82 81
Acute phase
Cardiogenic shock at randomization 3.7% 1.2% 0.315
Cardiogenic shock at follow-up 6.1% (new 2) 8.6% (new 6) 0.374
Major bleeding 9.8% 7.4% 0.400
Stroke after thrombolysis 2.4% 2.5% 0.685
30 days
CABG 0 0 1.000
Target lesion reintervention 2.4% 2.5% 0.685
Ischemic events 3.7% 24.7% 0.001
Reinfarction 2.4% 2.5% 0.685
Death 4.9% 9.9% 0.179
Death or reinfarction 7.3% 12.3% 0.208
Death, reinfarction, target lesion reintervention 7.3% 13.6% 0.146
Death, reinfarction, target lesion reintervention, ischemic events 8.5% 30.9% 0.001
6-months follow-up
Follow-up 272.4  191.0 days 302.0  255.8 days 0.404
CABG 7.3% 7.4% 0.609
Target lesion reintervention 19.5% 23.5% 0.336
Ischemic events 4.9% 28.4% 0.001
Reinfarction 2.4% 2.5% 0.685
Death 4.9% 11.1% 0.119
Death or reinfarction 7.3% 13.6% 0.146
Death, reinfarction, target lesion reintervention 24.4% 35.8% 0.078
Death, reinfarction, target lesion reintervention, ischemic events 25.6% 50.6% 0.001
LV ejection fraction
LV ejection fraction acute phase 52.2  12.6% NA
LV ejection fraction after two weeks 56.7  11.5%* 52.5  13.1%† 0.037
LV ejection fraction after six months 61.5  12.0%* 56.4  11.4%† 0.018
Left ventricular (LV) ejection fraction at different time points: two weeks versus six months immediate stenting group *p  0.015; delayed stenting group †p  0.082.
CABG  coronary artery bypass grafting; major bleeding  transfusion or surgery due to beleeding complication.
Table 6. End Points: Comparison of TIMI Flow Rates After Thrombolysis in the Two Groups
Immediate Stenting Delayed Stenting
p ValueTIMI 0/1 TIMI 2/3 TIMI 0/1 TIMI 2/3
n 17 65 18 63
LV ejection fraction acute phase 48.9  9.2% 53.0  13.2% NA NA
LV ejection fraction after two weeks 50.8  8.9%* 58.2  11.6%* 45.9  12.8%‡ 54.6  12.6%‡ 0.001
LV ejection fraction after six months 54.8  13.5%† 63.5  10.9%† 51.3  9.2%§ 57.8  11.6%§ 0.002
Target lesion reintervention 29.4% 16.9% 27.8% 22.2% 0.598
Ischemic events 5.9% 4.6% 50.0% 22.2% 0.001
Reinfarction 5.9% 1.5% 5.6% 1.6% 0.576
Death 0 6.2% 11.1% 11.1% 0.415
Death or reinfarction 5.9% 7.7% 16.7% 12.7% 0.574
Death, reinfarction, target lesion reintervention 29.4% 23.1% 44.4% 33.3% 0.308
Death, reinfarction, target lesion
reintervention, ischemic events
29.4% 24.6% 72.2%¶ 44.4%¶ 0.001
Comparison of patients with TIMI 0/1 vs. TIMI 2/3 within the immediate stenting group: *p 0.017, †p  0.013. Comparison of patients with TIMI 0/1 vs. TIMI 2/3 within
the delayed stenting group: ‡p  0.013, §p  0.079, p  0.025, ¶p  0.034.
LV  left ventricular; TIMI  Thrombolysis In Myocardial Infarction.
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angioplasty was even associated with higher mortality (12).
One reason for this finding may be intimal and medial
hemorrhage at the angioplasty site, leading to re-occlusion
of the IRA (17). Furthermore, beneficial effects of modern
antiplatelet therapy and device technology were not yet
available.
Patients randomized to thrombolytic therapy before
transfer for angioplasty in the Primary Angioplasty in AMI
Patients from General Community Hospitals Transported
to PTCA Units Versus Emergency Thrombolysis (PRA-
GUE) trial showed higher rates of bleeding (18). Only
patients with an occluded infarct-related vessel after throm-
bolysis have been shown to benefit from angioplasty (19).
However, the Primary Angioplasty with a Strategy of
Short-Acting Thrombolysis (PACT) study provided evi-
dence for a safe use of thrombolytic agents and angioplasty
(20). Only retrospective data indicate that the combination
of full dose pre-hospital thrombolysis and immediate an-
gioplasty with stent implantation is safe and achieves high
early patency rates (21).
In the present trial, immediate patient transfer within 6 h
for coronary angiography after thrombolysis was performed.
This concept would be suitable in daily life practice to
provide the earliest possible interventional therapy in the
majority of patients suffering from AMI in community
hospitals. A significant improvement in event-free survival
was achieved by immediate coronary stent implantation
after thrombolysis. The strategy of coronary angiography
with stenting after recovery and stabilization for two weeks
(or in some cases earlier in the presence of signs of
continuing or complicating ischemia) was observed to be
inferior to coronary intervention even when thrombolysis
was judged successful according to non-invasive measures.
Patients with failed reperfusion after thrombolysis in the
immediate intervention group showed an outcome similar
to that of patients who had undergone successful thrombol-
ysis. Furthermore, immediate intervention compared with
delayed intervention after two weeks produced a significant
improvement in LV function, which even increased during
the six months of follow-up. It has been reported that
myocardium at risk recovers within the first 14 days (22).
This fits well with the results of this study by the significant
improvement in LV ejection fraction noted already after 14
days. Mortality in the acute phase and during follow-up was
reduced by about 50%. However, the study was not de-
signed to show differences in mortality. For this purpose
larger trials are necessary. The use of GP IIb/IIIa antago-
nists was particularly uncommon in the early intervention
group.
It may be speculated that immediate stenting could
potentially be further improved by a combination of throm-
bolysis and GP IIb/IIIa antagonists.
Our results compare favorably with recently reported
outcomes of patients with acute coronary syndromes. The
Intracoronary Stenting With Antithrombotic Regimen
Cooling Off (ISAR-COOL) trial showed a significantly
worse outcome for patients in whom percutaneous coronary
intervention was delayed for 72 to 120 h while they were
given antiplatelet therapy, including GP IIb/IIIa antago-
nists, than for those undergoing immediate stenting (23).
However, lack of IIb/IIIa blockade may alter the benefits of
early invasive strategies in acute coronary syndromes
(ELISA) (24).
In summary, immediate transfer of patients to centers for
coronary angiography and stenting within 6 h after throm-
bolysis for AMI is safe and improves event-free survival, in
particular recurrent ischemia as well as LV function, com-
pared with elective stenting later on.
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